ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Association Between Circulating PLA2G12B and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) is a major microvascular complication of type 2 diabetes, and dysregulated lipid metabolism contributes to its progression. PLA2G12B is involved in lipid metabolism, yet its subcellular localization and detectability in human serum remain controversial. Clinical evidence regarding the association between circulating PLA2G12B and DKD is still limited. Aim: To explore the association between circulating PLA2G12B level and the probability of DKD and to perform exploratory analyses of lipid profiles across different disease statuses. Methods: A total of 230 participants were included in this cross-sectional study. Baseline clinical information, lipid parameters and serum PLA2G12B concentrations were measured. Multivariate logistic regression was applied to explore the association between serum PLA2G12B and DKD. Loess smoothing curves were used to visualize the changing trends, and stratified analyses were performed to evaluate potential interactions. Results: Elevated circulating PLA2G12B was independently associated with increased possibilities of DKD with a distinct threshold effect. Stratified subgroup analyses confirmed a consistent positive correlation across most subgroups and a significant interaction effect was detected for age tertiles. The trends between PLA2G12B and lipid/insulin resistance/atherogenic parameters across distinct disease stages highlight its stage-dependent role in lipid metabolism of diabetes. Conclusion: Our study identifies an association between circulating PLA2G12B and DKD among patients with type 2 diabetes. These observational findings provide clues for future research exploring biological pathways relevant to diabetic kidney injury, and further studies are required to characterize the clinical relevance of circulating PLA2G12B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.